Alpha Fetoprotein, CSF (Tumor Marker)
0020729
 
Ordering Recommendation
Mnemonic
AFP CSF
Methodology
Quantitative Chemiluminescent Immunoassay
Performed
Sun-Sat
Reported
Within 24 hours
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
CSF.  
Specimen Preparation
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.2 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Any specimens other than CSF.  
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 year  
Reference Interval
18 years or older: 0-1 ng/mL
Interpretive Data
The Beckman Coulter Access DxI AFP method is used. Results obtained with different assay methods or kits cannot be used interchangeably. AFP is a valuable aid in the management of nonseminomatous testicular cancer patients when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased AFP concentrations have also been observed in ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with and without liver metastases, and in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis, and cirrhosis. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females. This test is FDA cleared but is not labeled for use with CSF.

See Compliance Statement B: www.aruplab.com/CS
Note
CPT Code(s)
86316
Components
Component Test Code*Component Chart Name
0020729Alpha Fetoprotein, CSF (Tumor Marker)
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • AFP
  • AFP Tumor Marker
  • Alpha-Fetoprotein, CSF
  • CSF AFP
  • Fetoprotein, Alpha